Document is current

Article History

Received: 16 July 2021

Accepted: 9 November 2021

First Online: 19 November 2021

Declarations

:

: The study was approved by the institutional ethics review board of Shizuoka Cancer Centre (approval number: J2020-177-2020-1) and was conducted in accordance with the Declaration of Helsinki. The need for consent to participate was waived due to the retrospective nature of the study.

: Not applicable.

: HK (Kenmotsu) reports C/A and RF from Chugai Pharmaceutical Co, Ltd., C/A from Ono Pharmaceutical Co, Ltd., C/A from Boehringer Ingelheim, C/A from Eli Lilly K.K, C/A from Kyowa Hakko Kirin Co., Ltd., C/A from Bristol-Myers Squibb, C/A from MSD, C/A and RF from Novartis Pharma K.K., C/A and RF from Daiichi-Sankyo Co., Ltd., C/A and RF from AstraZeneca K.K., C/A from Pfizer, C/A from Taiho Pharma, outside the submitted work. NM reports C/A from AstraZeneca KK, Pfizer Japan, Inc., C/A from Chugai Pharmaceutical Co., Ltd., C/A and RF from Boehringer Ingelheim, C/A from MSD K.K., personal fees from TAIHO PHARMACEUTICAL CO., LTD., C/A from ONO PHARMACEUTICAL CO., LTD., outside the submitted work. HK (Kobayashi) reports C/A from Eli Lilly K.K, C/A from Taiho Pharmaceutical, personal fees from AstraZeneca, outside the submitted work. SO reports C/A from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical, AstraZeneca K.K., Boehringer Ingelheim, Taiho Pharmaceutical, and MSD, which are unrelated to the submitted work. RK reports C/A and RF from Boehringer Ingelheim, C/A and RF from AstraZeneca, C/A from Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Pfizer, and Lilly, outside the submitted work. KW reports C/A and RF from Chugai Pharmaceutical Co., Ltd., C/A from Taiho Pharmaceutical, C/A from Boehringer Ingelheim, C/A from Eli Lilly K.K., C/A from Ono Pharmaceutical, C/A from MSD, C/A and RF from AstraZeneca, RF from Novartis, RF from AbbVie, outside the submitted work. AO reports C/A from Taiho Pharmaceutical, C/A from Ono Pharmaceutical, C/A from Chugai Pharmaceutical Co., Ltd., C/A from Novartis Pharma K.K., outside the submitted work. HM reports C/A from AstraZeneca K.K., Ono Pharmaceutical, Bristol-Myers Squibb Japan, Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Novartis Pharma K.K., Boehringer Ingelheim, Taiho Pharmaceutical, Eli Lilly K.K., and MSD, which are unrelated to the submitted work. HH reports C/A and RF from Daiichi Sankyo Pharmaceutical Co. AstraZeneca K.K., Brain Labo Co., and Chugai Pharmaceutical Co., and RF from the Japan Agency for Medical Research and Development and the National Cancer Centre Research and Development Fund, which are unrelated to the submitted work. ME reports C/A from Ono Pharmaceutical, C/A from AstraZeneca, C/A from Takeda Pharmaceutical Co., Ltd., C/A from Daiichi-Sankyo Co., Ltd., outside the submitted work. KT reports C/A and RF AstraZeneca K.K., Pfizer Japan, Inc., Eli Lilly K.K., MSD, and Boehringer Ingelheim as well as grants from Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., GlaxoSmithKline Consumer Healthcare Japan K.K., SHIONOGI & CO., LTD., and Novartis Pharma K.K., which are unrelated to the submitted work. TT reports C/A and RF from AstraZeneca KK, Pfizer Japan, Inc., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Boehringer Ingelheim Japan, Inc., and Pfizer Japan, Inc., and Roche Diagnostics K.K., outside the submitted work. TM, HK (Kodama), NN, EM, TN, and, KM declare that they have no competing interests.